Rockville, Maryland – September 11, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.
REGENXBIO confirms back-to-back fireside chats on September 15 and 16
The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.
Webcasts open access to REGENXBIO's late-stage pipeline updates
Select fireside chats will be streamed live through the Investors section of REGENXBIO's corporate website, with archived replays available for approximately 30 days after each event. The conference appearances give institutional investors direct access to management ahead of continued clinical progress across the company's rare and retinal disease programs, including RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec and RGX-111 for MPS II and MPS I, and surabgene lomparvovec for wet AMD and diabetic retinopathy.